A Phase 2 interventional study of ASKP1240 and Tacrolimus in Kidney Transplantation, sponsored by Astellas Pharma Global Development, Inc.. Completed at 42 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy and safety of ASKP1240, an anti-CD40 monoclonal antibody, for the prophylaxis of organ rejection after kidney transplantation. This study will compare the efficacy of basiliximab induction, ASKP1240, mycophenolate mofetil (MMF), and steroids [calcineurin inhibitor (CNI) avoidance] to the standard of care immunosuppressive regimen (basiliximab induction + tacrolimus + MMF + steroids). In addition, the study will compare the efficacy of basiliximab induction, ASKP1240, tacrolimus and steroids [CNI minimization-MMF avoidance] to the standard of care immunosuppressive regimen (basiliximab induction + tacrolimus + MMF + steroids).
Subjects will be followed for 6 months. Upon completion of the first 6 months of the study, subjects may participate in the Long Term Extension period of the study. Subjects will remain on their original treatment arm up to three years post-transplant (and / or Sponsor discontinues development or the subject no longer wishes to participate in the study).
Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.
Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Basiliximab induction + Tacrolimus + MMF + Corticosteroids
Drug: Tacrolimus · Drug: Mycophenolate Mofetil (MMF) · Drug: Basiliximab · Drug: Methylprednisone · Drug: Prednisone
Basiliximab induction + ASKP1240 + MMF + Corticosteroids
Drug: ASKP1240 · Drug: Mycophenolate Mofetil (MMF) · Drug: Basiliximab · Drug: Methylprednisone · Drug: Prednisone
Basiliximab induction + ASKP1240 + Tacrolimus + Corticosteroids
Drug: ASKP1240 · Drug: Tacrolimus · Drug: Basiliximab · Drug: Methylprednisone · Drug: Prednisone
intravenous infusion
intravenous or oral
Also known as: Prograf®
intravenous or oral
Also known as: CellCept®
intravenous
Also known as: Simulect®
Intravenous
Oral
Biopsy-proven acute (T or B cell) rejection (BPAR) (Banff 2007 Grade ≥ 1) by local review
Time frame: 6 months
Glomerular Filtration Rate (GFR)
GFR is based on Modification of Diet in Renal Disease (4 variable-MDRD) criteria
Time frame: 6 months
Patient Survival
Subject survival is defined as any subject who does not die during the study.
Time frame: 6 months
Graft Survival
Graft survival is defined as any subject who does not experience graft loss during the study. Graft loss is defined as subject death, retransplantation, transplant nephrectomy, or the permanent return to dialysis (greater than 30 days).
Time frame: 6 months
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency.
Ran from Mar 2013 to primary completion in Jun 2014, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bleselumab · Tacrolimus · Mycophenolic Acid
Astellas Pharma Global Development, Inc. →